Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16ClNO2S.C6H6O3S |
Molecular Weight | 479.997 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC=C1.COC(=O)[C@@H](N2CCC3=C(C2)C=CS3)C4=CC=CC=C4Cl
InChI
InChIKey=CUZIJKLLBDXNFV-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.C6H6O3S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;7-10(8,9)6-4-2-1-3-5-6/h2-5,7,9,15H,6,8,10H2,1H3;1-5H,(H,7,8,9)/t15-;/m0./s1
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct
inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that
inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet
aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active
metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet
aggregation induced by agonists other than ADP is also inhibited by blocking the amplification
of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
6.9 null [pKi] | |||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia.
Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Preventing | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1500 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15800 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2520 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4600 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.521 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3130 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50600 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7440 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
9890 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.767 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
1.09 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, unknown |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Other AEs: Uric acid abnormal... |
1650 mg single, oral Overdose Dose: 1650 mg Route: oral Route: single Dose: 1650 mg Co-administed with:: phenytoin sodium(1400 mg; single) Sources: simvastatin(120 mg; single) |
unknown, 49 years n = 1 Health Status: unknown Age Group: 49 years Sex: M Population Size: 1 Sources: |
|
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Disc. AE: Transaminases increased, Fever... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Fever (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Uric acid abnormal | 5 patients | 600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Fever | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Transaminases increased | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Drug-induced thrombotic microangiopathy: incidence, prevention and management. | 2001 |
|
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence. | 2001 |
|
Novel platelet inhibitors. | 2001 |
|
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. | 2001 Apr |
|
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke. | 2001 Apr |
|
Results of CURE trial for acute coronary syndrome. | 2001 Apr 11 |
|
[Acute heart attacks. Prognosis can be further improved]. | 2001 Apr 5 |
|
Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data. | 2001 Aug |
|
Radiation-induced glomerular thrombus formation and nephropathy are not prevented by the ADP receptor antagonist clopidogrel. | 2001 Aug 1 |
|
Bench to bedside: the development of rapamycin and its application to stent restenosis. | 2001 Aug 21 |
|
Severe hypersensitivity associated with clopidogrel. | 2001 Aug 21 |
|
Acute myocardial infarction 2000 treatment. | 2001 Fall |
|
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. | 2001 Feb |
|
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. | 2001 Feb 15 |
|
[Clopidogrel? Known or known?]. | 2001 Jan |
|
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
|
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. | 2001 Jan 25 |
|
Clopidogrel (Plavix): hematological reactions. | 2001 Jan 9 |
|
[Can we use clopidogrel in patients with coronary stent?]. | 2001 Jan-Mar |
|
ADP receptors of platelets and their inhibition. | 2001 Jul |
|
Multiple intracranial aneurysms as delayed complications of an atrial myxoma: case report. | 2001 Jul |
|
Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena? | 2001 Jul-Aug |
|
[Toxic skin reaction to clopidogrel]. | 2001 Jun |
|
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. | 2001 Jun |
|
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. | 2001 Jun 15 |
|
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. | 2001 Jun 21 |
|
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. | 2001 Mar |
|
[New platelet inhibitors]. | 2001 Mar |
|
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation. | 2001 Mar |
|
Initial experience with a newer generation coronary stent. | 2001 Mar |
|
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. | 2001 May |
|
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. | 2001 May |
|
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings. | 2001 May 1 |
|
Clopidogrel and aplastic anaemia. | 2001 May 5 |
|
Coronary stent deployment in situs inversus. | 2001 Nov |
|
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. | 2001 Oct |
|
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. | 2001 Oct |
|
Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. | 2001 Sep |
|
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. | 2001 Sep |
|
Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review. | 2001 Sep |
|
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. | 2001 Sep |
|
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. | 2001 Sep 15 |
Sample Use Guides
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
The recommended daily dose of is 75 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10077233
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CLOPIDOGRAL HEXAL (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A-PHARMA (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN:
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
744256-69-7
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
PRIMARY | |||
|
DBSALT002628
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
PRIMARY | |||
|
SUB30714
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
PRIMARY | |||
|
BL9VGG8BHW
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
PRIMARY | |||
|
100000115443
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
PRIMARY | |||
|
9847991
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
PRIMARY | |||
|
DTXSID30225441
Created by
admin on Fri Dec 15 18:05:09 GMT 2023 , Edited by admin on Fri Dec 15 18:05:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD